Castle Creek Biosciences, Inc., a late-clinical stage cell and gene therapy company focused on therapies for rare genetic diseases, has acquired Novavita Thera, Inc., a preclinical gene therapy company focused on rare liver and metabolic diseases. The acquisition expands Castle Creek’s technology platform by adding in vivo capabilities to its existing ex vivo approach, and broadens Castle Creek’s development pipeline beyond skin and connective tissue disorders to rare liver diseases....